Cara Therapeutics, Inc. (NASDAQ:CARA) Short Interest Update

Cara Therapeutics, Inc. (NASDAQ:CARA) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 576,700 shares, a decline of 54.2% from the November 15th total of 1,260,000 shares. Based on an average trading volume of 541,600 shares, the short-interest ratio is currently 1.1 days. Currently, 1.3% of the shares of the company are short sold.

Institutional Investors Weigh In On Cara Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CARA. Disciplined Growth Investors Inc. MN lifted its stake in Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Cara Therapeutics during the third quarter worth $29,000. Finally, FMR LLC increased its holdings in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 32,789 shares in the last quarter. 44.66% of the stock is currently owned by institutional investors.

Cara Therapeutics Trading Up 0.2 %

NASDAQ CARA traded up $0.00 on Friday, hitting $0.26. 1,006,388 shares of the company’s stock were exchanged, compared to its average volume of 638,491. The stock has a 50-day moving average of $0.29 and a 200-day moving average of $0.34. Cara Therapeutics has a 52 week low of $0.24 and a 52 week high of $1.31. The stock has a market cap of $14.37 million, a price-to-earnings ratio of -0.15 and a beta of 0.64.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Cara Therapeutics in a report on Saturday, December 7th. They set a “sell” rating for the company. One investment analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $2.32.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.